Literature DB >> 15935395

Rimonabant: the first therapeutically relevant cannabinoid antagonist.

Mauro A M Carai1, Giancarlo Colombo, Gian Luigi Gessa.   

Abstract

The present paper synthetically reviews the multiple experimental lines of evidence indicating the ability of the prototypic cannabinoid CB(1) receptor antagonist, rimonabant (also known as SR 141716), to suppress the reinforcing/rewarding properties of different drugs of abuse, including cocaine, heroin, nicotine and alcohol, in laboratory rodents. This paper also reviews the data demonstrating that rimonabant reduces food intake and body weight in laboratory animals and humans. Taken together, the data reviewed here suggest that rimonabant may constitute a new and potentially effective medication for the treatment of drug addiction and obesity-related disorders.

Entities:  

Mesh：

Substances：

Year:  2005        PMID： 15935395     DOI： 10.1016/j.lfs.2005.04.017

Source DB:  PubMed          Journal:  Life Sci        ISSN： 0024-3205            Impact factor:   5.037


  24 in total

1.  In silico investigation of interactions between human cannabinoid receptor-1 and its antagonists.

Authors:  Guanglin Kuang; Guoping Hu; Xianqiang Sun; Weihua Li; Guixia Liu; Yun Tang
Journal:  J Mol Model       Date:  2012-03-09       Impact factor: 1.810

Review 2.  Hypothalamic regulatory pathways and potential obesity treatment targets.

Authors:  Erin E Jobst; Pablo J Enriori; Puspha Sinnayah; Michael A Cowley
Journal:  Endocrine       Date:  2006-02       Impact factor: 3.633

3.  Low dose naloxone attenuates the pruritic but not anorectic response to rimonabant in male rats.

Authors:  F L Wright; R J Rodgers
Journal:  Psychopharmacology (Berl)       Date:  2012-11-10       Impact factor: 4.530

4.  Effect of the cannabinoid CB1 receptor antagonist rimonabant on nociceptive responses and adjuvant-induced arthritis in obese and lean rats.

Authors:  T Croci; E Zarini
Journal:  Br J Pharmacol       Date:  2007-01-22       Impact factor: 8.739

5.  Rimonabant reduces keratinocyte viability by induction of apoptosis and exerts topical anti-inflammatory activity in mice.

Authors:  Anna Maria Malfitano; Silvio Sosa; Chiara Laezza; Marco De Bortoli; Aurelia Tubaro; Maurizio Bifulco
Journal:  Br J Pharmacol       Date:  2011-01       Impact factor: 8.739

6.  Synthesis and Pharmacological Evaluation of 1-Phenyl-3-Thiophenylurea Derivatives as Cannabinoid Type-1 Receptor Allosteric Modulators.

Authors:  Thuy Nguyen; Thomas F Gamage; Ann M Decker; Daniel Barrus; Tiffany L Langston; Jun-Xu Li; Brian F Thomas; Yanan Zhang
Journal:  J Med Chem       Date:  2019-10-24       Impact factor: 7.446

Review 7.  Endocannabinoids and the gastrointestinal tract: what are the key questions?

Authors:  G J Sanger
Journal:  Br J Pharmacol       Date:  2007-09-03       Impact factor: 8.739

8.  Rimonabant (SR141716) exerts anti-proliferative and immunomodulatory effects in human peripheral blood mononuclear cells.

Authors:  A M Malfitano; C Laezza; S Pisanti; P Gazzerro; M Bifulco
Journal:  Br J Pharmacol       Date:  2007-12-24       Impact factor: 8.739

9.  Lack of tolerance to the suppressing effect of rimonabant on chocolate intake in rats.

Authors:  Gian Luigi Gessa; Alessandro Orrù; Paola Lai; Paola Maccioni; Rossella Lecca; Carla Lobina; Mauro A M Carai; Giancarlo Colombo
Journal:  Psychopharmacology (Berl)       Date:  2006-02-21       Impact factor: 4.530

10.  Effects of the cannabinoid CB₁ receptor allosteric modulator ORG 27569 on reinstatement of cocaine- and methamphetamine-seeking behavior in rats.

Authors:  Li Jing; Yanyan Qiu; Yanan Zhang; Jun-Xu Li
Journal:  Drug Alcohol Depend       Date:  2014-08-17       Impact factor: 4.492
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.